Evidence map›Paper›PMID 42792602›Full record

ReviewBiology2026

PU.1 as a Master Regulator of Immune Cell Development and Function: Structural Basis, Gene Regulatory Networks, Disease Roles, and Therapeutic Targeting.

Mili Ramani, Ngoc Nguyen, Jamie Solis, Daniel G Tenen, Bon Q Trinh

Abstract readReview
In one paragraph

Review in Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mili RamaniDepartment of Pathology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA.
Ngoc NguyenDepartment of Life Sciences, Gachon University, Global Campus, Seongnam-si 13120, Republic of Korea.
Jamie SolisDepartment of Pathology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA.ORCID 0000-0003-3654-3747
Daniel G TenenHarvard Medical School Initiative for RNA Medicine, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-6423-3888
Bon Q TrinhDepartment of Pathology, University of Virginia School of Medicine, Charlottesville, VA 22908, USA.ORCID 0000-0002-0956-8941

Funding

Enhancer RNA-mediated Tumor Suppressor Gene Expression in Normal and Malignant HematopoiesisK01CA222707 · NCI · UNIVERSITY OF VIRGINIA · PI TRINH, BON Q · 2017 to 2021
$571k
The role of long noncoding RNAs in acute myeloid leukemiaR21CA270067 · NCI · UNIVERSITY OF VIRGINIA · PI TRINH, BON Q · 2024 to 2024
$415k
American Cancer Society 134088-IRG-19-143-33-IRGElsa U. Pardee FoundationNCI NIH HHS K01 CA222707NCI NIH HHS R21 CA270067State funding within the UVA Comprehensive Cancer Center and UVA School of MedicineUniversity of Virginia 4-VA
6 · The paper itself

Abstract

PU.1 is a hematopoietic ETS-family transcription factor that serves as a master regulator of immune cell development, lineage commitment, chromatin organization, and innate immune function. PU.1 is essential for the generation and maintenance of monocytes, macrophages, dendritic cells, granulocytes, and B lymphocytes, while its repression is required for T-cell lineage commitment. As a lineage-determining transcription factor, PU.1 establishes cell identity by binding enhancer elements, recruiting chromatin remodelers, and cooperating with partner factors such as C/EBPα, RUNX1, IRF8, and GATA factors. Tight quantitative control of PU.1 is critical, as both reduced and excessive activity can disrupt hematopoiesis and immunity. Dysregulation of PU.1 has been implicated in acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), lymphoid malignancies, chronic inflammatory disorders, fibrosis, and neurodegenerative disease. Recent structural and mechanistic advances have provided insights into the structure of PU.1, DNA recognition specificity, post-transcriptional regulation, and therapeutic vulnerabilities. In this review, we summarize current knowledge of PU.1 protein structure, regulatory mechanisms, binding partners, roles in disease, and emerging strategies to therapeutically target PU.1-centered networks.

Indexed as

development and functiondisease rolesgene regulatory networksimmune cellmaster regulatortherapeutic targeting

Identifiers

PMID42792602
PMCPMC13604644

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.